Dual targeting of CCR2 and CCR5: Therapeutic potential for immunologic and cardiovascular diseases

Journal of Leukocyte Biology

Volumn 88, Issue 1, 2010, Pages 41-55

  Zhao, Qihong ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chemokine receptors; Chemokines; Disease pathogenesis; Monocyte macrophage recruitment

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5;

ACUTE GRAFT REJECTION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC GRAFT REJECTION; CROHN DISEASE; DATA ANALYSIS; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNOPATHOLOGY; LEUKOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; TREATMENT PLANNING; ANIMAL; DRUG ANTAGONISM; HYPERPLASIA; INTIMA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CROHN DISEASE; GRAFT REJECTION; HUMANS; HYPERPLASIA; IMMUNE SYSTEM DISEASES; RECEPTORS, CCR2; RECEPTORS, CCR5; TUNICA INTIMA;

EID: 77954676361     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1009671     Document Type: Review

References (156)

1. Murphy, P. M. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54, 227-229.
2. Gerard, C., Rollins, B. J. (2001) Chemokines and disease. Nat. Immunol. 2, 108-115.
3. Charo, I. F., Ransohoff, R. M. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621.
4. Viola, A., Luster, A. D. (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48, 171-197.
5. Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R., O'Brien, S. J. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856-1862.
6. Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N. R., Phair, J., Ho, D. D., Koup, R. A. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2, 1240-1243.
7. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., Landau, N. R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
8. Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., Saragosti, S., Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart, G., Parmentier, M. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725.
9. Zimmerman, P. A., Buckler-White, A., Alkhatib, G., Spalding, T., Kubofcik, J., Combadiere, C., Weissman, D., Cohen, O., Rubbert, A., Lam, G., Vaccarezza, M., Kennedy, P. E., Kumaraswami, V., Giorgi, J. V., Detels, R., Hunter, J., Chopek, M., Berger, E. A., Fauci, A. S., Nutman, T. B., Murphy, P. M. (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3, 23-36.
10. Miller, L. H., Mason, S. J., Clyde, D. F., McGinniss, M. H. (1976) The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295, 302-304.
11. Tournamille, C., Colin, Y., Cartron, J. P., Le Van Kim, C. (1995) Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat. Genet. 10, 224-228.
12. Pease, J. E., Horuk, R. (2009) Chemokine receptor antagonists: part 1. Expert Opin. Ther. Pat. 19, 39-58.
13. Pease, J. E., Horuk, R. (2009) Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat. 19, 199-221.
14. Hunt, J. S., Romanelli, F. (2009) Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 29, 295-304.
15. Wagstaff, A. J. (2009) Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs 69, 319-326.
16. Charo, I. F., Peters, W. (2003) Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation 10, 259-264.
17. Ness, T. L., Kunkel, S. L., Hogaboam, C. M. (2006) CCR5 antagonists: the answer to inflammatory disease? Expert Opin. Ther. Pat. 16, 1051-1065.
18. Geissmann, F., Jung, S., Littman, D. R. (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71-82.
19. Sozzani, S., Luini, W., Borsatti, A., Polentarutti, N., Zhou, D., Piemonti, L., D'Amico, G., Power, C. A., Wells, T. N., Gobbi, M., Allavena, P., Mantovani, A. (1997) Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 159, 1993-2000.
20. Loetscher, P., Seitz, M., Baggiolini, M., Moser, B. (1996) Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184, 569-577.
21. Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese Jr., R. V., Broxmeyer, H. E., Charo, I. F. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100, 2552-2561.
22. Kuziel, W. A., Morgan, S. J., Dawson, T. C., Griffin, S., Smithies, O., Ley, K., Maeda, N. (1997) Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94, 12053-12058. (Pubitemid 27467841)
23. Kurihara, T., Warr, G., Loy, J., Bravo, R. (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186, 1757-1762. (Pubitemid 27506288)
24. Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., Rollins, B. J. (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187, 601-608. (Pubitemid 28093362)
25. Mack, M., Cihak, J., Simonis, C., Luckow, B., Proudfoot, A. E., Plachý, J., Brü hl, H., Frink, M., Anders, H. J., Vielhauer, V., Pfirstinger, J., Stangassinger, M., Schlöndorff, D. (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166, 4697-4704.
26. Brodmerkel, C. M., Huber, R., Covington, M., Diamond, S., Hall, L., Collins, R., Leffet, L., Gallagher, K., Feldman, P., Collier, P., Stow, M., Gu, X., Baribaud, F., Shin, N., Thomas, B., Burn, T., Hollis, G., Yeleswaram, S., Solomon, K., Friedman, S., Wang, A., Xue, C. B., Newton, R. C., Scherle, P., Vaddi, K. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 175, 5370-5378.
27. Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese Jr., R. V., Broxmeyer, H. E., Charo, I. F. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100, 2552-2561. (Pubitemid 27514895)
28. Kuziel, W. A., Morgan, S. J., Dawson, T. C., Griffin, S., Smithies, O., Ley, K., Maeda, N. (1997) Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94, 12053-12058. (Pubitemid 27467841)
29. Kurihara, T., Warr, G., Loy, J., Bravo, R. (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186, 1757-1762. (Pubitemid 27506288)
30. Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., Rollins, B. J. (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187, 601-608. (Pubitemid 28093362)
31. Serbina, N. V., Salazar-Mather, T. P., Biron, C. A., Kuziel, W. A., Pamer, E. G. (2003) TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19, 59-70.
32. Serbina, N. V., Pamer, E. G. (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7, 311-317.
33. Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese Jr., R. V., Broxmeyer, H. E., Charo, I. F. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100, 2552-2561. (Pubitemid 27514895)
34. Kuziel, W. A., Morgan, S. J., Dawson, T. C., Griffin, S., Smithies, O., Ley, K., Maeda, N. (1997) Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94, 12053-12058. (Pubitemid 27467841)
35. Kurihara, T., Warr, G., Loy, J., Bravo, R. (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186, 1757-1762.
36. Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., Rollins, B. J. (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187, 601-608.
37. Huo, Y., Weber, C., Forlow, S. B., Sperandio, M., Thatte, J., Mack, M., Jung, S., Littman, D. R., Ley, K. (2001) The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J. Clin. Invest. 108, 1307-1314.
38. Wu, L., Paxton, W. A., Kassam, N., Ruffing, N., Rottman, J. B., Sullivan, N., Choe, H., Sodroski, J., Newman, W., Koup, R. A., Mackay, C. R. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681-1691.
39. Oba, Y., Lee, J. W., Ehrlich, L. A., Chung, H. Y., Jelinek, D. F., Callander, N. S., Horuk, R., Choi, S. J., Roodman, G. D. (2005) MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol. 33, 272-278.
40. Schecter, A. D., Calderon, T. M., Berman, A. B., McManus, C. M., Fallon, J. T., Rossikhina, M., Zhao, W., Christ, G., Berman, J. W., Taubman, M. B. (2000) Human vascular smooth muscle cells possess functional CCR5. J. Biol. Chem. 275, 5466-5471. (Pubitemid 30115180)
41. Tyner, J. W., Uchida, O., Kajiwara, N., Kim, E. Y., Patel, A. C., O'Sullivan, M. P., Walter, M. J., Schwendener, R. A., Cook, D. N., Danoff, T. M., Holtzman, M. J. (2005) CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat. Med. 11, 1180-1187.
42. Katschke Jr., K. J., Rottman, J. B., Ruth, J. H., Qin, S., Wu, L., LaRosa, G., Ponath, P., Park, C. C., Pope, R. M., Koch, A. E. (2001) Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. 44, 1022-1032.
43. Crane, I. J., Xu, H., Wallace, C., Manivannan, A., Mack, M., Liversidge, J., Marquez, G., Sharp, P. F., Forrester, J. V. (2006) Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J. Leukoc. Biol. 79, 435-443.
44. Gong, J. H., Ratkay, L. G., Waterfield, J. D., Clark-Lewis, I. (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186, 131-137.
45. Rafei, M., Berchiche, Y. A., Birman, E., Boivin, M. N., Young, Y. K., Wu, J. H., Heveker, N., Galipeau, J. (2009) An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J. Immunol. 183, 1759-1766.
46. Youssef, S., Maor, G., Wildbaum, G., Grabie, N., Gour-Lavie, A., Karin, N. (2000) C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106, 361-371.
47. Ogata, H., Takeya, M., Yoshimura, T., Takagi, K., Takahashi, K. (1997) The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182, 106-114.
48. Schimmer, R. C., Schrier, D. J., Flory, C. M., Laemont, K. D., Tung, D., Metz, A. L., Friedl, H. P., Conroy, M. C., Warren, J. S., Beck, B., Ward, P. A. (1998) Streptococcal cell wall-induced arthritis: requirements for IL-4, IL-10, IFN-γ, and monocyte chemoattractant protein-1. J. Immunol. 160, 1466-1471.
49. Schrier, D. J., Schimmer, R. C., Flory, C. M., Tung, D. K., Ward, P. A. (1998) Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls. J. Leukoc. Biol. 63, 359-363.
50. Matsukawa, A., Miyazaki, S., Maeda, T., Tanase, S., Feng, L., Ohkawara, S., Yoshinaga, M., Yoshimura, T. (1998) Production and regulation of monocyte chemoattractant protein-1 in lipopolysaccharide- or monosodium urate crystal-induced arthritis in rabbits: roles of tumor necrosis factor α, interleukin-1, and interleukin-8. Lab. Invest. 78, 973-985.
51. Shahrara, S., Proudfoot, A. E., Park, C. C., Volin, M. V., Haines, G. K., Woods, J. M., Aikens, C. H., Handel, T. M., Pope, R. M. (2008) Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J. Immunol. 180, 3447-3456.
52. Brühl, H., Cihak, J., Plachý, J., Kunz-Schughart, L., Niedermeier, M., Denzel, A., Rodriguez Gomez, M., Talke, Y., Luckow, B., Stangassinger, M., Mack, M. (2007) Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 56, 2975-2985.
53. Andres, P. G., Beck, P. L., Mizoguchi, E., Mizoguchi, A., Bhan, A. K., Dawson, T., Kuziel, W. A., Maeda, N., MacDermott, R. P., Podolsky, D. K., Reinecker, H. C. (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte associated Th2-type immune response in the intestine. J. Immunol. 164, 6303-6312.
54. Khan, W. I., Motomura, Y., Wang, H., El-Sharkawy, R. T., Verdu, E. F., Verma-Gandhu, M., Rollins, B. J., Collins, S. M. (2006) Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G803-G811.
55. Abdi, R., Means, T. K., Ito, T., Smith, R. N., Najafian, N., Jurewicz, M., Tchipachvili, V., Charo, I., Auchincloss Jr., H., Sayegh, M. H., Luster, A. D. (2004) Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J. Immunol. 172, 767-775.
56. Lee, I., Wang, L., Wells, A. D., Ye, Q., Han, R., Dorf, M. E., Kuziel, W. A., Rollins, B. J., Chen, L., Hancock, W. W. (2003) Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J. Immunol. 171, 6929-6935.
57. Saiura, A., Sata, M., Hiasa, K., Kitamoto, S., Washida, M., Egashira, K., Nagai, R., Makuuchi, M. (2004) Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler. Thromb. Vasc. Biol. 24, 1886-1890. (Pubitemid 39350308)
58. Alexis, J. D., Pyo, R. T., Chereshnev, I., Katz, J., Rollins, B. J., Charo, I. F., Taubman, M. B. (2008) Inhibition of MCP-1/CCR2 signaling does not inhibit intimal proliferation in a mouse aortic transplant model. J. Vasc. Res. 45, 538-546.
59. Shimizu, K., Libby, P., Mitchell, R. N. (2005) Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc. Med. 15, 142-148.
60. Belperio, J. A., Keane, M. P., Burdick, M. D., Lynch III, J. P., Xue, Y. Y., Berlin, A., Ross, D. J., Kunkel, S. L., Charo, I. F., Strieter, R. M. (2001) Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J. Clin. Invest. 108, 547-556. (Pubitemid 32777734)
61. Boring, L., Gosling, J., Cleary, M., Charo, I. F. (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897. (Pubitemid 28410911)
62. Dawson, T. C., Kuziel, W. A., Osahar, T. A., Maeda, N. (1999) Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143, 205-211. (Pubitemid 29138720)
63. Veillard, N. R., Steffens, S., Pelli, G., Lu, B., Kwak, B. R., Gerard, C., Charo, I. F., Mach, F. (2005) Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 112, 870-878. (Pubitemid 41170074)
64. Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., Rollins, B. J. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2, 275-281. (Pubitemid 128373654)
65. Gosling, J., Slaymaker, S., Gu, L., Tseng, S., Zlot, C. H., Young, S. G., Rollins, B. J., Charo, I. F. (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778.
66. Ni, W., Egashira, K., Kitamoto, S., Kataoka, C., Koyanagi, M., Inoue, S., Imaizumi, K., Akiyama, C., Nishida, K. I., Takeshita, A. (2001) New antimonocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103, 2096-2101.
67. Inoue, S., Egashira, K., Ni, W., Kitamoto, S., Usui, M., Otani, K., Ishibashi, M., Hiasa, K., Nishida, K., Takeshita, A. (2002) Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106, 2700-2706.
68. Ni, W., Kitamoto, S., Ishibashi, M., Usui, M., Inoue, S., Hiasa, K., Zhao, Q., Nishida, K., Takeshita, A., Egashira, K. (2004) Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 24, 534-539. (Pubitemid 38326149)
69. Yamashita, T., Kawashima, S., Ozaki, M., Namiki, M., Inoue, N., Hirata, K., Yokoyama, M. (2002) Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler. Thromb. Vasc. Biol. 22, 969-974. (Pubitemid 34655225)
70. Eto, Y., Shimokawa, H., Tanaka, E., Morishige, K., Fuchigami, M., Ishiwata, Y., Matsushima, K., Takeshita, A. (2003) Long-term treatment with propagermanium suppresses atherosclerosis in WHHL rabbits. J. Cardiovasc. Pharmacol. 41, 171-177. (Pubitemid 36135240)
71. Shimokawa, H., Eto, Y., Miyata, K., Morishige, K., Kandabashi, T., Matsushima, K., Takeshita, A. (2003) Propagermanium suppresses macrophage-mediated formation of coronary arteriosclerotic lesions in pigs in vivo. J. Cardiovasc. Pharmacol. 41, 372-380. (Pubitemid 36255296)
72. Roque, M., Kim, W. J., Gazdoin, M., Malik, A., Reis, E. D., Fallon, J. T., Badimon, J. J., Charo, I. F., Taubman, M. B. (2002) CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler. Thromb. Vasc. Biol. 22, 554-559. (Pubitemid 34408733)
73. Schober, A., Zernecke, A., Liehn, E. A., von Hundelshausen, P., Knarren, S., Kuziel, W. A., Weber, C. (2004) Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ. Res. 95, 1125-1133.
74. Kim, W. J., Chereshnev, I., Gazdoiu, M., Fallon, J. T., Rollins, B. J., Taubman, M. B. (2003) MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem. Biophys. Res. Commun. 310, 936-942.
75. Eefting, D., Bot, I., de Vries, M. R., Schepers, A., van Bockel, J. H., Van Berkel, T. J., Biessen, E. A., Quax, P. H. (2009) Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. J. Vasc. Surg. 50, 152-160.
76. Egashira, K., Zhao, Q., Kataoka, C., Ohtani, K., Usui, M., Charo, I. F., Nishida, K., Inoue, S., Katoh, M., Ichiki, T., Takeshita, A. (2002) Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ. Res. 90, 1167-1172.
77. Schepers, A., Eefting, D., Bonta, P. I., Grimbergen, J. M., de Vries, M. R., van Weel, V., de Vries, C. J., Egashira, K., van Bockel, J. H., Quax, P. H. (2006) Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 26, 2063-2069.
78. Furukawa, Y., Matsumori, A., Ohashi, N., Shioi, T., Ono, K., Harada, A., Matsushima, K., Sasayama, S. (1999) Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ. Res. 84, 306-314. (Pubitemid 29095571)
79. Usui, M., Egashira, K., Ohtani, K., Kataoka, C., Ishibashi, M., Hiasa, K., Katoh, M., Zhao, Q., Kitamoto, S., Takeshita, A. (2002) Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J. 16, 1838-1840.
80. Mori, E., Komori, K., Yamaoka, T., Tanii, M., Kataoka, C., Takeshita, A., Usui, M., Egashira, K., Sugimachi, K. (2002) Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105, 2905-2910. (Pubitemid 34666106)
81. Ohtani, K., Usui, M., Nakano, K., Kohjimoto, Y., Kitajima, S., Hirouchi, Y., Li, X. H., Kitamoto, S., Takeshita, A., Egashira, K. (2004) Antimonocyte chemoattractant protein-1 gene therapy reduces experimental instent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther. 11, 1273-1282. (Pubitemid 39173434)
82. Egashira, K., Nakano, K., Ohtani, K., Funakoshi, K., Zhao, G., Ihara, Y., Koga, J., Kimura, S., Tominaga, R., Sunagawa, K. (2007) Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol. 27, 2563-2568.
83. Tatewaki, H., Egashira, K., Kimura, S., Nishida, T., Morita, S., Tominaga, R. (2007) Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation. J. Vasc. Surg. 45, 1236-1243. (Pubitemid 46817835)
84. Horvath, C., Welt, F. G., Nedelman, M., Rao, P., Rogers, C. (2002) Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. 90, 488-494. (Pubitemid 34633920)
85. Nakano, K., Egashira, K., Ohtani, K., Zhao, G., Funakoshi, K., Ihara, Y., Sunagawa, K. (2007) Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis 194, 309-316. (Pubitemid 47513092)
86. Quinones, M. P., Ahuja, S. K., Jimenez, F., Schaefer, J., Garavito, E., Rao, A., Chenaux, G., Reddick, R. L., Kuziel, W. A., Ahuja, S. S. (2004) Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113, 856-866.
87. Quinones, M. P., Jimenez, F., Martinez, H., Estrada, C. A., Willmon, O., Dudley, M., Kuziel, W. A., Melby, P. C., Reddick, R. L., Ahuja, S. K., Ahuja, S. S. (2006) CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium. J. Mol. Med. 84, 503-512.
88. Brühl, H., Cihak, J., Schneider, M. A., Plachý, J., Rupp, T., Wenzel, I., Shakarami, M., Milz, S., Ellwart, J. W., Stangassinger, M., Schlöndorff, D., Mack, M. (2004) Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol. 172, 890-898.
89. Haringman, J. J., Gerlag, D. M., Smeets, T. J., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., Schmouder, R., Woodworth, T., Tak, P. P. (2006) A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387-2392.
90. Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., van den Bosch, F., Dinant, H. J., Lee, Y., Wyant, T., Jacobson, E. W., Baeten, D., Tak, P. P. (2008) Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931-1939.
91. Bao, L., Zhu, Y., Zhu, J., Lindgren, J. U. (2005) Decreased IgG production but increased MIP-1β expression in collagen-induced arthritis in C-C chemokine receptor 5-deficient mice. Cytokine 31, 64-71.
92. Vierboom, M. P., Zavodny, P. J., Chou, C. C., Tagat, J. R., Pugliese-Sivo, C., Strizki, J., Steensma, R. W., McCombie, S. W., Celebi-Paul, L., Remarque, E., Jonker, M., Narula, S. K., Hart, B. (2005) Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 52, 627-636.
93. Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., Saragosti, S., Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart, G., Parmentier, M. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725.
94. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., Landau, N. R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
95. Garred, P., Madsen, H. O., Petersen, J., Marquart, H., Hansen, T. M., Freiesleben Sørensen, S., Volck, B., Svejgaard, A., Andersen, V. (1998) CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. 25, 1462-1465.
96. Gómez-Reino, J. J., Pablos, J. L., Carreira, P. E., Santiago, B., Serrano, L., Vicario, J. L., Balsa, A., Figueroa, M., de Juan, M. D. (1999) Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 42, 989-992.
97. Pokorny, V., McQueen, F., Yeoman, S., Merriman, M., Merriman, A., Harrison, A., Highton, J., McLean, L. (2005) Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann. Rheum. Dis. 64, 487-490.
98. Zapico, I., Coto, E., Rodríguez, A., Alvarez, C., Torre, J. C., Alvarez, V. (2000) CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 1, 288-289.
99. Cooke, S. P., Forrest, G., Venables, P. J., Hajeer, A. (1998) The Δ32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum. 41, 1135-1136.
100. Prahalad, S. (2006) Negative association between the chemokine receptor CCR5-Δ32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 7, 264-268.
101. Prahalad, S., Bohnsack, J. F., Jorde, L. B., Whiting, A., Clifford, B., Dunn, D., Weiss, R., Moroldo, M., Thompson, S. D., Glass, D. N., Bamshad, M. J. (2006) Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun. 7, 468-475.
102. Yang, Y. F., Mukai, T., Gao, P., Yamaguchi, N., Ono, S., Iwaki, H., Obika, S., Imanishi, T., Tsujimura, T., Hamaoka, T., Fujiwara, H. (2002) A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol. 32, 2124-2132.
103. Gao, P., Zhou, X. Y., Yashiro-Ohtani, Y., Yang, Y. F., Sugimoto, N., Ono, S., Nakanishi, T., Obika, S., Imanishi, T., Egawa, T., Nagasawa, T., Fujiwara, H., Hamaoka, T. (2003) The unique target specificity of a non-peptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol. 73, 273-280.
104. Tokuyama, H., Ueha, S., Kurachi, M., Matsushima, K., Moriyasu, F., Blumberg, R. S., Kakimi, K. (2005) The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol. 17, 1023-1034.
105. Gao, W., Faia, K. L., Csizmadia, V., Smiley, S. T., Soler, D., King, J. A., Danoff, T. M., Hancock, W. W. (2001) Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72, 1199-1205.
106. Li, J., Zhang, K., Ye, P., Wang, S., Xia, J. (2009) CCR5 blockade in combination with rapamycin prolongs cardiac allograft survival in mice. Clin. Exp. Immunol. 157, 437-445.
107. Amano, H., Bickerstaff, A., Orosz, C. G., Novick, A. C., Toma, H., Fairchild, R. L. (2005) Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts. J. Immunol. 174, 6499-6508. (Pubitemid 40663845)
108. Nozaki, T., Amano, H., Bickerstaff, A., Orosz, C. G., Novick, A. C., Tanabe, K., Fairchild, R. L. (2007) Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J. Immunol. 179, 5238-5245.
109. Abdi, R., Smith, R. N., Makhlouf, L., Najafian, N., Luster, A. D., Auchincloss Jr., H., Sayegh, M. H. (2002) The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51, 2489-2495. (Pubitemid 34827398)
110. Yang, L., Liu, Y. F., Wu, G., Zhang, J. L., Wang, F. S., Fu, D. Z., Zhao, G. H., Li, T. M. (2007) Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival. Transplant. Proc. 39, 185-190. (Pubitemid 46175953)
111. Schröder, C., Pierson III, R. N., Nguyen, B. N., Kawka, D. W., Peterson, L. B., Wu, G., Zhang, T., Springer, M. S., Siciliano, S. J., Iliff, S., Ayala, J. M., Lu, M., Mudgett, J. S., Lyons, K., Mills, S. G., Miller, G. G., Singer, I. I., Azimzadeh, A. M., DeMartino, J. A. (2007) CCR5 blockade modulates inflammation and alloimmunity in primates. J. Immunol. 179, 2289-2299.
112. Schnickel, G. T., Bastani, S., Hsieh, G. R., Shefizadeh, A., Bhatia, R., Fishbein, M. C., Belperio, J., Ardehali, A. (2008) Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J. Immunol. 180, 4714-4721.
113. Yun, J. J., Whiting, D., Fischbein, M. P., Banerji, A., Irie, Y., Stein, D., Fishbein, M. C., Proudfoot, A. E., Laks, H., Berliner, J. A., Ardehali, A. (2004) Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 109, 932-937.
114. Fischereder, M., Luckow, B., Hocher, B., Wüthrich, R. P., Rothenpieler, U., Schneeberger, H., Panzer, U., Stahl, R. A., Hauser, I. A., Budde, K., Neumayer, H., Krämer, B. K., Land, W., Schlöndorff, D. (2001) CC chemokine receptor 5 and renal-transplant survival. Lancet 357, 1758-1761.
115. Braunersreuther, V., Zernecke, A., Arnaud, C., Liehn, E. A., Steffens, S., Shagdarsuren, E., Bidzhekov, K., Burger, F., Pelli, G., Luckow, B., Mach, F., Weber, C. (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 27, 373-379.
116. Quinones, M. P., Martinez, H. G., Jimenez, F., Estrada, C. A., Dudley, M., Willmon, O., Kulkarni, H., Reddick, R. L., Fernandes, G., Kuziel, W. A., Ahuja, S. K., Ahuja, S. S. (2007) CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195, e92-e103.
117. Veillard, N. R., Kwak, B., Pelli, G., Mulhaupt, F., James, R. W., Proudfoot, A. E., Mach, F. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94, 253-261. (Pubitemid 38197459)
118. Braunersreuther, V., Steffens, S., Arnaud, C., Pelli, G., Burger, F., Proudfoot, A., Mach, F. (2008) A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol. 28, 1090-1096.
119. Zernecke, A., Liehn, E. A., Gao, J. L., Kuziel, W. A., Murphy, P. M., Weber, C. (2006) Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 107, 4240-4243. (Pubitemid 43801346)
120. Krohn, R., Raffetseder, U., Bot, I., Zernecke, A., Shagdarsuren, E., Liehn, E. A., van Santbrink, P. J., Nelson, P. J., Biessen, E. A., Mertens, P. R., Weber, C. (2007) Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116, 1812-1820.
121. Schober, A., Manka, D., von Hundelshausen, P., Huo, Y., Hanrath, P., Sarembock, I. J., Ley, K., Weber, C. (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106, 1523-1529.
122. Farivar, A. S., Krishnadasan, B., Naidu, B. V., Woolley, S. M., Mulligan, M. S. (2003) The role of the β chemokines in experimental obliterative bronchiolitis. Exp. Mol. Pathol. 75, 210-216. (Pubitemid 37373707)
123. Akashi, S., Sho, M., Kashizuka, H., Hamada, K., Ikeda, N., Kuzumoto, Y., Tsurui, Y., Nomi, T., Mizuno, T., Kanehiro, H., Hisanaga, M., Ko, S., Nakajima, Y. (2005) A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80, 378-384.
124. Schröppel, B., Zhang, N., Chen, P., Zang, W., Chen, D., Hudkins, K. L., Kuziel, W. A., Sung, R., Bromberg, J. S., Murphy, B. (2004) Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J. Am. Soc. Nephrol. 15, 1853-1861.
125. Aiello, R. J., Bourassa, P. A., Lindsey, S., Weng, W., Natoli, E., Rollins, B. J., Milos, P. M. (1999) Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 1518-1525.
126. Yokochi, S., Hashimoto, H., Ishiwata, Y., Shimokawa, H., Haino, M., Terashima, Y., Matsushima, K. (2001) An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. J. Interferon Cytokine Res. 21, 389-398.
127. Guo, J., de Waard, V., Van Eck, M., Hildebrand, R. B., van Wanrooij, E. J., Kuiper, J., Maeda, N., Benson, G. M., Groot, P. H., Van Berkel, T. J. (2005) Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler. Thromb. Vasc. Biol. 25, 1014-1019.
128. Davidson, M., Lekstrom-Himes, J., Gilbert, J., Donaldson, D., Lee, Y., Hu, M., Xu, J., MLN1202 in ACSVD Study Group (2007) Abstract 874. MLN1202, a novel CCR2 antagonist, decreases C-reactive protein in patients at risk for atherosclerotic cardiovascular disease in a double blind placebo controlled study. Circulation 116, II-171.
129. Kuziel, W. A., Dawson, T. C., Quinones, M., Garavito, E., Chenaux, G., Ahuja, S. S., Reddick, R. L., Maeda, N. (2003) CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167, 25-32.
130. McDermott, D. H., Fong, A. M., Yang, Q., Sechler, J. M., Cupples, L. A., Merrell, M. N., Wilson, P. W., D'Agostino, R. B., O'Donnell, C. J., Patel, D. D., Murphy, P. M. (2003) Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111, 1241-1250.
131. Chvatchko, Y., Proudfoot, A. E., Buser, R., Juillard, P., Alouani, S., Kosco- Vilbois, M., Coyle, A. J., Nibbs, R. J., Graham, G., Offord, R. E., Wells, T. N. (2003) Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J. Immunol. 171, 5498-5506.
132. Potteaux, S., Combadière, C., Esposito, B., Casanova, S., Merval, R., Ardouin, P., Gao, J. L., Murphy, P. M., Tedgui, A., Mallat, Z. (2005) Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol. Med. 11, 16-20.
133. Braunersreuther, V., Zernecke, A., Arnaud, C., Liehn, E. A., Steffens, S., Shagdarsuren, E., Bidzhekov, K., Burger, F., Pelli, G., Luckow, B., Mach, F., Weber, C. (2007) Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 27, 373-379.
134. Potteaux, S., Combadière, C., Esposito, B., Lecureuil, C., Ait-Oufella, H., Merval, R., Ardouin, P., Tedgui, A., Mallat, Z. (2006) Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26, 1858-1863. (Pubitemid 44305341)
135. van Wanrooij, E. J., Happé, H., Hauer, A. D., de Vos, P., Imanishi, T., Fujiwara, H., van Berkel, T. J., Kuiper, J. (2005) HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 2642-2647. (Pubitemid 43732291)
136. Combadière, C., Potteaux, S., Rodero, M., Simon, T., Pezard, A., Esposito, B., Merval, R., Proudfoot, A., Tedgui, A., Mallat, Z. (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117, 1649-1657.
137. Tacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., Lira, S. A., Habenicht, A. J., Randolph, G. J. (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 185-194.
138. Combadière, C., Potteaux, S., Gao, J. L., Esposito, B., Casanova, S., Lee, E. J., Debré, P., Tedgui, A., Murphy, P. M., Mallat, Z. (2003) Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107, 1009-1016. (Pubitemid 36258725)
139. Lesnik, P., Haskell, C. A., Charo, I. F. (2003) Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111, 333-340. (Pubitemid 36182209)
140. Gautier, E. L., Jakubzick, C., Randolph, G. J. (2009) Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29, 1412-1418.
141. Fantuzzi, L., Borghi, P., Ciolli, V., Pavlakis, G., Belardelli, F., Gessani, S. (1999) Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. Blood 194, 875-883. (Pubitemid 29361817)
142. Kaufmann, A., Salentin, R., Gemsa, D., Sprenger, H. (2001) Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 α during differentiation of human monocytes to macrophages. J. Leukoc. Biol. 69, 248-252. (Pubitemid 32163437)
143. Katschke Jr., K. J., Rottman, J. B., Ruth, J. H., Qin, S., Wu, L., LaRosa, G., Ponath, P., Park, C. C., Pope, R. M., Koch, A. E. (2001) Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. 44, 1022-1032.
144. Raport, C. J., Gosling, J., Schweickart, V. L., Gray, P. W., Charo, I. F. (1996) Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1β, and MIP-1α. J. Biol. Chem. 271, 17161-17166.
145. Berger, E. A., Murphy, P. M., Farber, J. M. (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700.
146. Glass, W. G., Lim, J. K., Cholera, R., Pletnev, A. G., Gao, J. L., Murphy, P. M. (2005) Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087-1098.
147. Glass, W. G., McDermott, D. H., Lim, J. K., Lekhong, S., Yu, S. F., Frank, W. A., Pape, J., Cheshier, R. C., Murphy, P. M. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40.
148. Lim, J. K., Louie, C. Y., Glaser, C., Jean, C., Johnson, B., Johnson, H., McDermott, D. H., Murphy, P. M. (2008) Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197, 262-265.
149. Kindberg, E., Mickiene, A., Ax, C., Akerlind, B., Vene, S., Lindquist, L., Lundkvist, A., Svensson, L. (2008) A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266-269.
150. Serbina, N. V., Jia, T., Hohl, T. M., Pamer, E. G. (2008) Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421-452.
151. Telenti, A. (2009) Safety concerns about CCR5 as an antiviral target. Curr. Opin. HIV AIDS 4, 131-135.
152. Dambach, D. M., Watson, L. M., Gray, K. R., Durham, S. K., Laskin, D. L. (2002) Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology 35, 1093-1103.
153. Ajuebor, M. N., Hogaboam, C. M., Le, T., Swain, M. G. (2003) C-C chemokine ligand 2/monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J. Immunol. 170, 5252-5259.
154. Ajuebor, M. N., Aspinall, A. I., Zhou, F., Le, T., Yang, Y., Urbanski, S. J., Sidobre, S., Kronenberg, M., Hogaboam, C. M., Swain, M. G. (2005) Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J. Immunol. 174, 8027-8037.
155. Ajuebor, M. N., Wondimu, Z., Hogaboam, C. M., Le, T., Proudfoot, A. E., Swain, M. G. (2007) CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 170, 1975-1988.
156. Emmelkamp, J. M., Rockstroh, J. K. (2007) CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions - review of the literature. Eur. J. Med. Res. 12, 409-417.